Novartis participated in a series B round that raised $50m for Pear Therapeutics, the creator of a software platform that assists substance abuse treatment.
US-based digital therapeutics software developer Pear Therapeutics closed a $50m series B round featuring pharmaceuticals producer Novartis yesterday.
The round was led by Singaporean state-owned investment firm Temasek and featured EDBI, an investment arm of the Singapore Economic Development Board, as well as 5AM Ventures, Arboretum Ventures and Bridge Builders Collaborative.
Pear has created a prescription-level neurobehavioural software platform to support treatment of drug use disorders. The product, which tracks cravings and relapses, was cleared by US healthcare regulator the…
